StockWireNews
Today's Trade Update Plus Huge Revenue Growth News Gives This "Green Wave" Profile Special Upside Potential
Based On The Following Report, See Why Mota Ventures Corp. Could Be Thursday's Breakout Idea
(OTC: PEMTF) (CSE: MOTA) (FSE: 1WZ1)
June 10th
Good Evening,
The opening bell is less than 15 hours away and there is one specific "Green Wave" stock that you need on your radar right now.
But, before we get there, I need to bring back to your attention today's profile, FUV, a NASDAQ idea that surged approximately 31% intraday.
Hitting a new 52-week high of $4.479 today, FUV is a profile you will need to keep on your watch-list short-term as another vertical surge could be right around the corner.
Mota Ventures Corp. (PEMTF) is an established ecommerce retailer of CB products in Europe and the USA that plans to vertically integrate their brands to become a low cost, high quality global exporter and distributor of CB products.
Currently, PEMTF looks like an undervalued stock due to recent corporate actions that have started to bring buzz to the company.
If more news (like 6/10's press release below) continues to pop up, Wall Street will begin to take notice of this green wave stock flying under-the-radar.
#1 PEMTF Potential Catalyst - Today's Major Revenue News
Mota Ventures Reports Monthly Revenues of Cdn$5.1Mn for Natures Exclusive, Highest in the History of the Brand, Representing, an Increase of 110% from May 2019
VANCOUVER, BC, CANADA / ACCESSWIRE / June 10, 2020 / Mota Ventures Corp. (CSE:MOTA) (FSE:1WZ1)(OTC PINK:PEMTF) (the "Company") the Company's subsidiary, Nature's Exclusive, an eCommerce provider of CB products to consumers in the United States, is pleased to announce an all-time monthly revenue record achieved during May 2020. Revenue for the month of May totaled Cdn$5.1Mn, representing an increase of 110% compared to May 2019. Expenses totaled Cdn$4.9Mn for the month, representing gross gains of Cdn$149K for May 2020.
The Company's investment in customer acquisition continues to yield benefits with the brand acquiring 23,141 new customers during the month of May 2020. The Company's strong ability to continue to acquire and retain new customers for its products continues to accelerate. As consumers continue to seek natural health product solutions, the Nature's Exclusive brand is well positioned to offer consumers quality and convenience.
NATURE'S EXCLUSIVE CB BRAND LEADING THE WAY
The Company's Nature's Exclusive brand offers a CB hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Nature's Exclusive offers a range of products, which include CB oil drops, CB gummies, CB pain relief cream, CB skin serum and CB coffee.
"I am very pleased our Nature's Exclusive brand achieved another monthly sales record. We continued to expand in the United States, and our outlook for the second half of fiscal 2020 is very positive. We remain on track to achieve our goals for 2020 despite the recent economic turmoil," stated Ryan Hoggan, CEO of the Company.
[...]
The Company cautions that figures for revenue, expenses and margin generated from the sale of Nature's Exclusive products in fiscal year 2020 have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from USD into Canadian currency using the Bank of Canada monthly average exchange rate of US$1.00:Cdn$1.397 for May 2020 and US$1.00:Cdn$1.3459 for May 2019.
-----
#2 PEMTF Potential Catalyst - Huge Acquisition News Update
Mota Ventures Signs Binding Term Sheet to Acquire E-Commerce Platform Leader Unified Funding with C$93.8Mn in Consumer Transactions Facilitated In
VANCOUVER, BC / ACCESSWIRE / June 6, 2020 / Mota Ventures Corp. (the "Company") is pleased to announce that it has entered into a binding term sheet (the "Term Sheet") dated June 5, 2020 with Unified Funding LLC ("Unified"). The term sheet replaces the previous preliminary letter of intent entered into with Unified on May 21, 2020.
Ryan Hoggan, Chief Executive Officer stated, "The very nature of CB, natural health products and psy*che*delics ("PSY") unequivocally points the future of our nascent industry into digital targeting, marketing and engagement of customers who will turn to the web to learn about and acquire the right products for them. Mota has already demonstrated superior eCommerce capabilities in 2020 but this acquisition of Unified will make us a formidable presence in the space."
Hoggan added, "From a shareholder value point of view, the one thing the biggest tech companies in the world have in common - according to McKinsey - is that they are all platform-based organizations that owe much of their success to the agility with which they are able to innovate and reconfigure themselves to go after new opp's. With this acquisition, we hope to establish a platform that will serve a growing global industry going forward."
PLATFORM HAS FACILITATED C$364MN IN TRANSACTIONS SINCE 2015, C$93.8MN IN 2019
Unified is a leading eCommerce platform company established in 2015 by partners with over a decade experience in eCommerce marketing. Unified has developed a proprietary technology platform along with a CRM designed specifically for emerging, small and medium sized eCommerce businesses worldwide. To date, the platform has successfully facilitated over CDN$364Mn in consumer transactions, including CDN$93Mn in 2019 alone.
The platform generates revenue from licensing, marketing and product fulfillment fees supporting brands in the natural health products sector, including skin care, nutraceutical, essential oils and CB. Unified brings the platform and experience needed for the Company to expand its product portfolio and brands. Integration of the platform with the Unified experienced team of professionals to run it will allow the Company to develop new products and enter new natural healthcare markets, aided significantly by Unified's ability to closely track current trends through a global network of media partners.
Kevin Keranen, Chairman of Unified, stated "Along with a diverse team of eCommerce experts, we have built one of the most comprehensive eCommerce platforms in the natural health products sector. Our combination of technology with a full team of individuals dedicated to specific segments of the business allows us to deliver robust growth for our clients. As we look to become a part of Mota, we will be able to access the growth capital to further expand our marketing efforts and support any initiative drive by the Company in a more strategic manner."
-----
#3 PEMTF Potential Catalyst - Company Closes Big Acquisition
Mota Ventures Closes $20Mn Acquisition of European Pharmaceutical Manufacturer of Natural Psi*lo*cybin ("PSI") Extracts
VANCOUVER, BC / ACCESSWIRE / June 2, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the "Company") a leading ecommerce provider of CB products to consumers in the United States and Europe, is pleased to announce the completion of its' Cdn$20Mn acquisition (the "Transaction") of all of the outstanding share capital of Verrian Ontario Ltd. ("Verrian") effective June 1, 2020. Verrian is an established and well advanced European PSY medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.
Ryan Hoggan, CEO of the Company stated, "The massive shift towards PSY derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade. Unlike some companies that use PSY as a marketing term, this acquisition of Verrian brings Mota market ready products, world renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion this is the most complete PSY asset on the market, and therefore should immediately make Mota a market leader in the space."
Hoggan further added, "In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CB sales. We intend to bring that same market expertise to bear with our PSY business in 2020 and far beyond."
ACQUISTION PROVIDES MOTA WITH IMMEDIATE ENTRY INTO FAST GROWING $100BN PSY INDUSTRY
The market for PSY derived medicines and therapies is estimated to be as high as USD$100Bn*. Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using PSY, including PSI.
As a result, PSY research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent LGLization of CB in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the PSY industry.
Verrian has already developed two PSI products that are natural PSI extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs. This is only the beginning with further products in various stages of development.
ESTABLISHED EUROPEAN PSY MEDICINE COMPANY
Verrian owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10.6Mn and include an analytical laboratory and full pharmaceutical manufacturing suite.
Verrian operates three distinct business segments:
- Pharmaceutical Manufacturing - A portfolio of medical & wellness products
- Phyto API - API creation from medical plants
- Analytical Testing - European Medicine Agency Standards
PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION
Verrian's singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of PSI demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.
To date Verrian has developed two PSI products: PSI GEN and PSI GEN+. These PSI products are focused on opiate addiction reduction. As natural PSI extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.
All of Verrian's compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.
GOALS AND VISION
In addition to the facility and equipment outlined above, Verrian has invested approximately Cdn$2.4Mn in clinical trial design and development of proprietary formulations for its PSI trademarked PSI-GEN products, and CB products, including trademarked CB*Daily and CBNight.
Verrian's world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and PSI refinement and production for micro dosing.
In consideration for the acquisition of all of the outstanding share capital of Verrian, the Company has issued 54,347,826 common shares (the "Consideration Shares") to the existing shareholders of Verrian at a deemed price of $0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company has arranged for repayment of $150K of existing shareholder loans of Verrian, and will arrange for repayment of the balance of $950K within sixty days of closing.
The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Company has paid a finders' fee of 5,434,783 common shares to certain arms'-length parties who have assisted in facilitating the Transaction. The Company has also paid an administrative fee of 1,086,957 common shares of the Company to a consultant who assisted with the Transaction.
-----
More About Mota Ventures Corp. (PEMTF)
From the company's IR Presentation:
GLOBAL VISION
Branding Rollout
North America: Acquired an established CB brand with existing sales and gains in the United States. Integrate production of CB products.
Europe: Acquired an established CB brand with existing sales and partnered with a European CB distributor. Expand First Class CB to Europe. Integrate extraction and production of CB products.
Latin America: Build out a greenhouse and extraction lab for non-PSY (CB), for production and distribution of low cost CB branded products. Establish a CB brand for Latin American region.
TARGET MARKET
US - Europe - Latin America
- CB Global market size is expected to surpass $32Bn by 2022.
- It is estimated that by 2023 the pain medication market will increase to over $1.5Tn.
- European CB Market is expected to grow 400% by 2023 with a total value of $1.7Bn.
- 20% of Europe's Population suffers from Chronic Pain, spending $285Bn annually on pain medication.
GROWTH STRATEGY
- Growth of existing brands through capital inv.estment targeted in customer acquisition.
- Expansion of existing brands into new markets, including Europe, the United States and Latin America.
- Vertically integrate eCommerce supply chain with Colombian cultivation and extraction assets to realize margin efficiencies.
- Expand product line to quickly meet consumer and new market demands.
www.motaventuresco.com/
-----
Coverage officially initiated on PEMTF.
